Currently, dopaminomimetics and monoamine oxidase B (MAO-B) inhibitors are utilized to suppress dopamine decomposition in PD therapy, nevertheless, they simply treat symptoms and have severe side effects [1]
Ramipril-treated individuals had more normoglycemia relapses
13-16 High Blood Pressure High blood pressure is the second most common cause of kidney failure after diabetes
They may recommend supplements and can advise on the dosage
Injectable GHK-Cu, now legally compoundable after the April 2026 reclassification, requires a physicians prescription from a licensed 503A compounding pharmacy following USP 797 sterile compounding standards
No regulatory authority Health Canada, the FDA, the EMA, the TGA, or any equivalent has cleared BPC-157 for therapeutic use in humans or animals